<DOC>
	<DOCNO>NCT00517829</DOCNO>
	<brief_summary>The purpose research study find effect ( good bad ) docetaxel , oxaliplatin , cetuximab gastric GEJ cancer .</brief_summary>
	<brief_title>Docetaxel+Oxali+/-Cetux Met Gastric/GEJ</brief_title>
	<detailed_description>This Phase II , open- label , randomize , noncomparative study . Patients stratified randomization ECOG PS . There intent equal number patient PS ( ie , 0 , 1 , 2 ) , rather stratification conduct ensure 2 treatment arm well-balanced ECOG PS . Patients randomly assign either Arm 1 - Taxotere 60 mg/m2 intravenous ( IV ) infusion 1 hour , follow Eloxatin 130 mg/m2 IV 2 hour Arm 2 - Taxotere 60 mg/m2 IV infusion 1 ho ur , follow Eloxatin 130mg/m2 IV 2 hour , follow ERBITUX 400 mg/m2 IV 120 minute ( first dose ) , dose 250 mg/m2 60 minute . Taxotere Eloxatin give Day 1 21-day cycle ; ERBITUX give Days 1 , 8 , 15 cycle . Treatment continue disease progression intolerable toxicity . Patients achieve CR receive additional 2 cycle treatment . Patients limit 24 month participation , count date first dose study drug .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patient histologically confirm Stage IV adenocarcinoma GEJ/stomach Note : Adjuvant radiation plus treatment 5FU leucovorin permit , require . Patients must measurable disease Patient Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 02 Patient great 18 year age If present , preexist ( current ) peripheral neuropathy must â‰¤ Grade 1 Patient 's laboratory value must fall within limit set forth section 4.2 protocol Patient negative serum pregnancy test within 7 day prior registration ( female patient childbearing potential ) If fertile , patient ( male female ) agree use acceptable method birth control avoid pregnancy duration study 2 month period thereafter Patient ( guardian ) sign Patient Informed Consent Form Patient ( guardian ) sign Patient Authorization Form Patient metastatic disease define section 4.2 ( criterion # 1 ) Patient prior treatment include anything adjuvant radiation plus treatment 5FU leucovorin . Prior treatment must complete &gt; 6 month prior registration current study . No prior regimen allow . Note : Adjuvant radiation plus treatment 5FU leucovorin permit , require . If present , peripheral neuropathy &gt; Grade 1 Patient know hypersensitivity Taxotere ( drug formulate Polysorbate80 ) , Eloxatin Has prior severe infusion reaction ( Grade 4 ) monoclonal antibody Has receive prior therapy , time , specifically directly target EGFR pathway Patient receive concurrent immunotherapy concurrent treatment cancer Has prior stem cell bone marrow transplant organ transplant exception corneal transplant cadaver bone graft Has significant history uncontrolled cardiac disease ; ie , uncontrolled hypertension , unstable angina , recent myocardial infarction ( within prior 6 month ) , uncontrolled congestive heart failure , cardiomyopathy decrease ejection fraction ( LVEF &lt; 50 % ) Has evidence CNS involvement ( CNS imaging require study enrollment unless clinically suspect CNS disease present . ) Patient serious uncontrolled intercurrent medical psychiatric illness , include serious infection Patient know HIV positive history hepatitis B C Patient history malignancy within last 5 year ( except squamous basal cell carcinoma skin , carcinoma situ cervix , superficial transitional cell carcinoma bladder ) , could affect diagnosis assessment current condition . Patient pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>metastatic gastric adenocarcinoma GE junction</keyword>
</DOC>